Literature DB >> 2513459

Primary systemic amyloidosis--a diagnostic primer.

M A Gertz1, R A Kyle.   

Abstract

Primary systemic amyloidosis (immunoglobulin light chain-derived) (AL) is an uncommon dysproteinemia with highly varied initial clinical manifestations. Among 153 patients with this disorder, the median survival was 20.4 months (5-year survival, 19.6%). The worst outcome was associated with overt congestive heart failure (median survival, 7.7 months; 5-year survival, 2.4%). The patients with the best outcome were those who had amyloid neuropathy without associated cardiac or renal involvement (median survival, 39.7 months; 5-year survival, 31.6%). Serum protein electrophoresis and immunoelectrophoresis are the most important tests because a monoclonal protein can be detected in almost two-thirds of the patients. When screening of both serum and urine is performed, a monoclonal protein is found in 86% of patients. Such screening is helpful if primary systemic amyloidosis is to be detected and treated early.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513459     DOI: 10.1016/s0025-6196(12)65706-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  37 in total

1.  Association between clinical characteristics and AL amyloid deposition in the kidney.

Authors:  Mitsuyo Itabashi; Takashi Takei; Misao Tsukada; Hidekazu Sugiura; Keiko Uchida; Ken Tsuchiya; Kazuho Honda; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Subacute liver failure secondary to amyloid light-chain amyloidosis.

Authors:  Theresa J Hydes; Richard J Aspinall
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

3.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

4.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

5.  Duodenal perforation in primary systemic amyloidosis.

Authors:  A G Fraser; G I Nicholson
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

6.  Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).

Authors:  Angela Dispenzieri; Giampaolo Merlini; Raymond L Comenzo
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

7.  Altered dimer interface decreases stability in an amyloidogenic protein.

Authors:  Elizabeth M Baden; Barbara A L Owen; Francis C Peterson; Brian F Volkman; Marina Ramirez-Alvarado; James R Thompson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

Review 8.  New insights and modern treatment of AL amyloidosis.

Authors:  Chakra P Chaulagain; Raymond L Comenzo
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

9.  Etanercept therapy in patients with advanced primary amyloidosis.

Authors:  M A Hussein; J V Juturi; L Rybicki; S Lutton; B R Murphy; M A Karam
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

10.  Patterns of neuropathy and autonomic failure in patients with amyloidosis.

Authors:  Annabel K Wang; Robert D Fealey; Tonette L Gehrking; Phillip A Low
Journal:  Mayo Clin Proc       Date:  2008-11       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.